ABSTRACT
BACKGROUND: Since 2019, the SARS-CoV-2 pandemic has become a global issue due to its high fatality rate. Over time, the characteristics of the virus have evolved and led to the creation of an omicron strain with higher infectivity but a significantly decreased fatality rate. For patients in urgent need of hematopoietic stem cell transplantation (HSCT), whether the SARS-CoV-2 infection status of donors has a significant impact on HSCT recipients should be clarified. METHODS: To estimate the transplantation risk of SARS-CoV-2-positive donors, 24 patients who underwent HSCT from December 1, 2022 to January 30, 2023 were retrospectively included. The ratio of the observation group (SARS-CoV-2-positive donors, n = 12) to the control group (SARS-CoV-2-negative donors, n = 12) was 1:1. We observed the time of hematopoietic reconstruction, donor chimerism, severe infection, acute graft vs host disease, and hepatic vein occlusion disease during hematopoietic reconstruction. RESULTS: In the observation group, the average time of myeloid hematopoietic reconstruction was 11.58 days, and in the control group, it was 12.17 days (P = .3563 [>.05]). On average, all patients achieved a 90% donor chimerism rate of +13.58 (±4.5) days (P = .5121 [>.05]). The average percentage of patients that achieved successful hematopoietic reconstruction was 96.75% in the observation group and 96.31% in the control group (P = .7819 [>.05]). A total of 6 adverse events occurred during this study: 3 in the observation group and 3 in the control group. CONCLUSIONS: Our preliminary results showed favorable short-term outcomes in recipients of SARS-CoV-2-positive HCST donors.
ABSTRACT
Background Since 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has become a global issue due to its high fatality rate. Over time, the characteristics of the virus have evolved and led to the creation of an omicron strain with higher infectivity but a significantly decreased fatality rate. For patients in urgent need of hematopoietic stem cell transplantation (HSCT), whether the SARS-CoV-2 infection status of donors has a significant impact on HSCT recipients should be clarified. Methods To estimate the transplantation risk of SARS-CoV-2-positive donors, 24 patients who underwent HSCT from December 1, 2022, to January 30, 2023, were retrospectively included. The ratio of the observation group (SARS-CoV-2-positive donors, n=12) to the control group (SARS-CoV-2-negative donors, n=12) was 1:1. We observed the time of hematopoietic reconstruction, donor chimerism, severe infection, acute graft versus host disease (aGVHD) and hepatic vein occlusion disease (VOD) during hematopoietic reconstruction. Results In the observation group, the average time of myeloid hematopoietic reconstruction was 11.58 d, and in the control group, it was 12.17 d. P= 0.3563 (>0.05)). On average, all patients achieved a 90% donor chimerism rate of +13.58 (±4.5) d. P=0.5121 (>0.05). The average percentage of patients that achieved successful hematopoietic reconstruction was 96.75% in observation group and 96.31% in control group. P=0.7819 (P>0.05). A total of 6 adverse events occurred during this study: 3 in the observation group and 3 in the control group. Conclusions Our preliminary results showed favorable short-term outcomes in recipients of SARS-CoV-2-positive HCST donors.
ABSTRACT
BACKGROUND: The world is currently struggling with the Coronavirus disease 2019 (COVID-19) pandemic. Dietary supplements (DSs) and herbal medicine provide a potentially convenient and accessible method for its recovery, but direct evidence is limited. OBJECTIVE: This study aims to investigate the effectiveness of DSs and herbs in patients with COVID-19. METHODS: A systematic literature search was conducted in multiple electronic English and Chinese databases. Randomized controlled trials (RCTs) involving DSs or herbal medicine interventions on patients with COVID-19 from November 2019 to February 2021 were included. Data was extracted, summarized and critically examined. RESULTS: Out of 9402 records identified in the initial search, twelve RCTs were included in this review. Risk of bias of these RCTs was deemed high. Most of the trials were of low methodologic quality. Nine studies showed herbal supplements were beneficial to the recovery of COVID-19 patients; zinc sulfate could shorten the duration of loss of smell but not total recovery from COVID-19. No severe adverse events were reported. CONCLUSION: Herbal supplements may help patients with COVID-19, zinc sulfate is likely to shorten the duration of olfactory dysfunction. DS therapy and herbal medicine appear to be safe and effective adjuvant therapies for patients with COVID-19. These results must be interpreted with caution due to the overall low quality of the included trials. More well-designed RCTs are needed in the future.